141 related articles for article (PubMed ID: 32033125)
21. Drug delivery strategies for combination ophthalmic treatments.
Kuppermann BD
Retina; 2009 Jun; 29(6 Suppl):S24-6. PubMed ID: 19553793
[TBL] [Abstract][Full Text] [Related]
22. Retinal pigment epithelium and microglia express the CD5 antigen-like protein, a novel autoantigen in age-related macular degeneration.
Iannaccone A; Hollingsworth TJ; Koirala D; New DD; Lenchik NI; Beranova-Giorgianni S; Gerling IC; Radic MZ; Giorgianni F
Exp Eye Res; 2017 Feb; 155():64-74. PubMed ID: 27989757
[TBL] [Abstract][Full Text] [Related]
23. Local configuration pattern features for age-related macular degeneration characterization and classification.
Mookiah MR; Acharya UR; Fujita H; Koh JE; Tan JH; Noronha K; Bhandary SV; Chua CK; Lim CM; Laude A; Tong L
Comput Biol Med; 2015 Aug; 63():208-18. PubMed ID: 26093788
[TBL] [Abstract][Full Text] [Related]
24. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
Tolentino MJ; Dennrick A; John E; Tolentino MS
Expert Opin Investig Drugs; 2015 Feb; 24(2):183-99. PubMed ID: 25243494
[TBL] [Abstract][Full Text] [Related]
25. Establishment of a drug evaluation model against light-induced retinal degeneration using adult pigmented zebrafish.
Saito Y; Tsuruma K; Shimazawa M; Nishimura Y; Tanaka T; Hara H
J Pharmacol Sci; 2016 Jul; 131(3):215-8. PubMed ID: 27430989
[TBL] [Abstract][Full Text] [Related]
26. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU
Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737
[TBL] [Abstract][Full Text] [Related]
27. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
[TBL] [Abstract][Full Text] [Related]
28. Protective effect of RIPK1-inhibitory compound in in vivo models for retinal degenerative disease.
Jang KH; Do YJ; Koo TS; Choi JS; Song EJ; Hwang Y; Bae HJ; Lee JH; Kim E
Exp Eye Res; 2019 Mar; 180():8-17. PubMed ID: 30500363
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the Ocular Penetration and Pharmacokinetics Between Natamycin and Voriconazole After Topical Instillation in Rabbits.
Zhao X; Tong Y; Wang X; Zhang X; Chen S; Lu H
J Ocul Pharmacol Ther; 2018; 34(6):460-467. PubMed ID: 29792548
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic Profile of Kaurenoic Acid after Oral Administration of Araliae Continentalis Radix Extract Powder to Humans.
Choi EJ; Choi GW; Yang SJ; Lee YB; Cho HY
Pharmaceutics; 2018 Dec; 10(4):. PubMed ID: 30513750
[TBL] [Abstract][Full Text] [Related]
31. Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*.
Fukuda M; Sasaki H
Curr Med Res Opin; 2008 Dec; 24(12):3479-86. PubMed ID: 19032129
[TBL] [Abstract][Full Text] [Related]
32. Nutritional supplements in age-related macular degeneration.
Schmidl D; Garhöfer G; Schmetterer L
Acta Ophthalmol; 2015 Mar; 93(2):105-21. PubMed ID: 25586104
[TBL] [Abstract][Full Text] [Related]
33. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.
Bussing D; K Shah D
J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799
[TBL] [Abstract][Full Text] [Related]
34. Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection.
Wu Q; Liu D; Zhang X; Wang D; DongYe M; Chen W; Lin D; Zhu F; Chen W; Lin H
Drug Deliv; 2019 Dec; 26(1):290-299. PubMed ID: 30895841
[TBL] [Abstract][Full Text] [Related]
35. Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973.
Richer SP; Stiles W; Graham-Hoffman K; Levin M; Ruskin D; Wrobel J; Park DW; Thomas C
Optometry; 2011 Nov; 82(11):667-680.e6. PubMed ID: 22027699
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of age-related macular degeneration and therapeutic opportunities.
van Lookeren Campagne M; LeCouter J; Yaspan BL; Ye W
J Pathol; 2014 Jan; 232(2):151-64. PubMed ID: 24105633
[TBL] [Abstract][Full Text] [Related]
37. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
Myles ME; Neumann DM; Hill JM
Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous determination of bioactive components of Radix Angelicae Sinensis-Radix Paeoniae Alba herb couple in rat plasma and tissues by UPLC-MS/MS and its application to pharmacokinetics and tissue distribution.
Luo N; Li Z; Qian D; Qian Y; Guo J; Duan JA; Zhu M
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():29-39. PubMed ID: 24927419
[TBL] [Abstract][Full Text] [Related]
39. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
[TBL] [Abstract][Full Text] [Related]
40. The penetration and distribution of topical atropine in animal ocular tissues.
Wang LZ; Syn N; Li S; Barathi VA; Tong L; Neo J; Beuerman RW; Zhou L
Acta Ophthalmol; 2019 Mar; 97(2):e238-e247. PubMed ID: 30259687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
